What is the market cap of ARWR?
Arrowhead Pharmaceuticals, traded under the ticker ARWR, commands a market capitalization in the double-digit billions in U.S. dollars. Its total market value is driven by high investor optimism surrounding its proprietary RNA interference therapeutics platform, major pharmaceutical licensing agreements, and clinical development pipelines targeting challenging genetic and metabolic diseases.
Related FAQs
Wall Street equity research analysts maintain an overwhelmingly bullish consensus on Amazon (AMZN), with approximately 96% of covering analysts rating the stock as a Buy and a 12-month median price target hovering around $295 per share.
Wall Street research analysts covering Arrowhead Pharmaceuticals, Inc. (ARWR) establish consensus 12-month average price targets centering around $96.92 per share.
Evaluating Arrowhead Pharmaceuticals (ticker ARWR) as an equity investment requires analyzing its innovative RNA interference therapeutic pipeline, clinical trial milestones, and major pharmaceutical partnership agreements.
Arrowhead Pharmaceuticals operates within strict bioethical and regulatory compliance standards established by international health authorities, institutional review boards, and government regulatory agencies for clinical drug development.
Armstrong ceiling tiles are manufactured using a diverse range of durable, acoustic-rated materials tailored for commercial and residential architectural applications.
Cohen & Steers, Inc. is a prominent specialized global investment management firm recognized as an industry leader in real estate securities, real assets, and alternative income strategies.
An analyst price target is a financial equity researcher's projected future price for a publicly traded stock over a specific time horizon, typically twelve months.
ARWR stock represents the publicly traded equity shares of Arrowhead Pharmaceuticals, Inc., a prominent biotechnology enterprise listed on the NASDAQ global select market.
Astronics Corporation is a leading global supplier of advanced technologies, lighting, electrical power systems, and avionics structures for the aerospace, defense, and semiconductor industries.
Arrowhead Pharmaceuticals focuses on discovering and developing innovative therapeutics designed to treat genetically driven conditions by utilizing its proprietary targeted RNA interference platform.
Equity research analysts covering Arrowhead Pharmaceuticals, Inc. (ARWR) maintain a strong consensus buy rating, supported by institutional enthusiasm for its proprietary RNA interference (RNAi) therapeutic discovery platform.
Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, is based in Pasadena, California, United States.
Wall Street analysts view Pfizer Inc.
The ticker symbol ARWR represents shares of Arrowhead Pharmaceuticals, Inc., a publicly traded biotechnology company listed on the Nasdaq stock exchange.
Evaluating the share price volatility of Eagers Automotive—traded on the Australian Securities Exchange under the ticker APE—reveals a moderate to high volatility profile characteristic of consumer discretionary retail and automotive dealership group...
Equity research analysts tracking Arrowhead Pharmaceuticals, Inc. formulate price predictions based on clinical pipeline milestones, RNA interference therapeutic platform advancements, and strategic pharmaceutical partnerships.
Determining if Arrowhead Pharmaceuticals represents a compelling long-term stock involves assessing its scientific leadership in gene silencing technologies and its ability to commercialize breakthrough RNAi therapeutics.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a clinical-stage biopharmaceutical enterprise specializing in the development of novel therapies for central nervous system disorders.